期刊文献+

卵巢原发性黑色素瘤合并成熟性畸胎瘤1例

Ovarian primary malignant melanoma complicated with mature teratoma: report of a case
原文传递
导出
摘要 卵巢成熟性畸胎瘤1%~3%会发生恶变,主要恶变为鳞状细胞癌,少见腺癌、肉瘤和类癌,恶变为黑色素瘤更为罕见,约占0.1%。现报道1例卵巢原发性黑色素瘤合并成熟性畸胎瘤,此肿瘤术前诊断困难,需要术后病理明确诊断,且目前没有既定的治疗指南,预后差。现结合本例的临床病理特征并复习相关文献,对原发性黑色素瘤合并成熟性畸胎瘤进行分析讨论,以提高临床及病理医师对该类肿瘤的认识,避免误诊。
作者 田颖 杨思昂 严琴 田芳 赵洁 Tian Ying;Yang Siang;Yan Qin;Tian Fang;Zhao Jie(Department of Pathology,Gansu Maternity and Child Health Care Hospital,Lanzhou 730050,China)
出处 《中华病理学杂志》 CAS CSCD 北大核心 2022年第8期779-781,共3页 Chinese Journal of Pathology
  • 相关文献

参考文献1

二级参考文献22

  • 1Hauschild A,Agarwala SS,Trefzer U,et al. Results of a phase III ,randomized,placebo-controlled study of so- rafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma [J]. J Clin Oncol,2009,27(17): 2823-2830.
  • 2McDermott DF,Sosman JA,Gonzalez R,et al. Double- blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma:a report from the 11715 Study Group [J].J Clin Oncol,2008,26(13) : 2178-2185.
  • 3Amaravadi RK, Schuchter LM, McDermott DF,et al. Phase II trial of Temozolomide and Sorafenib in advanced melanoma patients with or without brain metastases [J]. Clin Cancer Res, 2009,15 (24) : 7711-7718.
  • 4Chapman PB, Hauschild A, Robert C,et al. Improved sur- vival with vemurafenib in melanoma with BRAF V6OOE mutation[J]. N Engl J Med, 2011,364(26) : 2507-2516.
  • 5Falchook GS,Long GV,Kurzrock R,et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours:a phase 1 dose-escalation trial [J]. Lancet, 2012,379(9829) : 1893-1901.
  • 6Ascierto PA,Minor D,Ribas A,et al. Phase II trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436)in patients with metastatic melanoma [J]. J Clin Oncol, 2013,31(26) : 3205-3211.
  • 7Hauschild A,Grob JJ,Demidov LV,et al. Dabrafenib in BRAF -mutated metastatic melanoma : a multicentre, open- label, phase 3 randomised controlled trial[J]. Lancet,2012, 380(9839) : 358-365.
  • 8Kong Y,Si L,Zhu YY,et al. Large-scale analysis of KIT aberrations in Chinese patients with melanoma [J]. Clin Cancer Res ,2011 , 17(7): 1684-1691.
  • 9Guo J,Si L,Kong Y,Flaherty KT,et al. Phase II ,open- label,single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kitmutation or amplifica- t ion[J ]. J Clin Oneol, 2011,29(21) : 2904-2909.
  • 10Hodi FS, Corless CI,, Giobbie-Hurder A,et al. Imatinib for melanomas harboring mutationally activated or amplified kit arising on mucosal,acral,andchronically sun-damaged skin[J]. J Clin Oncol, 2013,31 (26) : 3182-3190.

共引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部